NEW YORK (GenomeWeb News) – CombiMatrix today reported that its third-quarter revenues increased 5 percent as the firm continued to shift its focus to prenatal testing.

The Irvine, Calif.-based molecular diagnostics firm reported total revenues of $1.3 million for the three months ended Sept. 30, compared to $1.2 million for the third quarter of 2011.

It brought in $1.1 million from diagnostic services during the quarter, down from $1.2 million the previous year. The quarter included $195,000 in clinical trials support through a program with Affymetrix.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.